News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medgenics, Inc. Announces First Patient Implanted In Phase 1/2 Clinical Trial Of MDGN-201 (EPODURE)


6/5/2014 9:18:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WAYNE, Pa. and MISGAV, Israel, June 5, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that the first patient has been enrolled in its Phase 1/2 clinical trial of MDGN-201 (EPODURETM).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES